Edition:
India

Galmed Pharmaceuticals Ltd (GLMD.OQ)

GLMD.OQ on NASDAQ Stock Exchange Capital Market

10.91USD
8:41pm IST
Change (% chg)

$0.07 (+0.65%)
Prev Close
$10.84
Open
$10.45
Day's High
$11.37
Day's Low
$10.45
Volume
15,000
Avg. Vol
9,809
52-wk High
$12.00
52-wk Low
$3.90

Chart for

About

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate,... (more)

Overall

Beta: 2.60
Market Cap(Mil.): $117.83
Shares Outstanding(Mil.): 12.64
Dividend: --
Yield (%): --

Financials

BRIEF-Galmed Pharma Raised Gross Proceeds Of $11.6 Mln Under ATM Programs During Dec. 2017

* GALMED PHARMACEUTICALS RAISED GROSS PROCEEDS OF $11.6 MILLION UNDER ATM PROGRAMS DURING DECEMBER 2017 Source text for Eikon: Further company coverage:

02 Jan 2018

BRIEF-683 Capital Management Llc Reports 5.1 Pct Passive Stake In Galmed Pharmaceuticals Ltd As Of Dec 6

* 683 CAPITAL MANAGEMENT LLC REPORTS 5.1 PERCENT PASSIVE STAKE IN GALMED PHARMACEUTICALS LTD AS OF DEC 6 - SEC FILING Source text: (http://bit.ly/2oG4CRl) Further company coverage:

19 Dec 2017

BRIEF-Galmed Pharmaceuticals Q3 loss per share $0.23

* Galmed Pharmaceuticals reports third quarter 2017 financial results and provides business update

09 Nov 2017

BRIEF-Galmed Pharmaceuticals announces ‍publication of a paper entitled "role of aramchol in steatohepatitis and fibrosis in mice"

* Galmed Pharmaceuticals Ltd - ‍publication of a paper entitled "role of aramchol in steatohepatitis and fibrosis in mice" in hepatology communications

05 Oct 2017

BRIEF-Galmed Pharmaceuticals announces pricing of offering to existing investors, members of board

* Galmed Pharmaceuticals announces pricing of offering of ordinary shares to existing investors and members of the board of directors

04 Aug 2017

BRIEF-Galmed Pharmaceuticals reports Q2 loss per share of $0.22

* Galmed Pharmaceuticals reports second quarter 2017 financial results and provides business update

31 Jul 2017

Earnings vs. Estimates